Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 436
- Registration Number
- NCT00306215
- Locations
- 🇦🇺
The Alfred Hospital, Prahran, Victoria, Australia
🇦🇹Krankenanstalt Rudolfstiftung, Wien, Austria
🇨🇦Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)
Phase 2
Completed
- Conditions
- MDSRefractory CytopeniasThrombocytopeniaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 72
- Registration Number
- NCT00303472
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
Phase 2
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 247
- Registration Number
- NCT00293813
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
Phase 3
Completed
- Conditions
- Hormone Refractory Prostate Cancer
- Interventions
- Biological: DenosumabBiological: Placebo
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1435
- Registration Number
- NCT00286091
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
Phase 1
Completed
- Conditions
- Chemotherapy-Induced ThrombocytopeniaHodgkin's LymphomaNon-Hodgkin's LymphomaCancerOncologyThrombocytopenia
- Interventions
- Biological: AMG 531
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2011-06-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 39
- Registration Number
- NCT00283439
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Phase 4
Completed
- Conditions
- NeutropeniaBreast CancerLung CancerNon-Hodgkin's LymphomaOvarian Cancer
- Interventions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2010-10-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 852
- Registration Number
- NCT00277160
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 110
- Registration Number
- NCT00261950
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 80
- Registration Number
- NCT00261313
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 96
- Registration Number
- NCT00259740
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT00254267
© Copyright 2025. All Rights Reserved by MedPath